» Articles » PMID: 38990460

Endocrine-disrupting Effects of Bisphenol-A, Thiamethoxam, and Fipronil in Hormone-naïve Transmen Compared to Cis-women

Overview
Specialty Endocrinology
Date 2024 Jul 11
PMID 38990460
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Current evidence suggests that the etiology of gender dysphoria (GD) is multifactorial: this, however, remains unclear. Endocrine-disrupting chemicals (EDCs) are one of the etiological hypotheses.

Objectives: In this study, we aimed to evaluate the urinary levels of bisphenol A (BPA), thiamethoxam, and fipronil in hormone-naïve transmen compared with case-matched cis-women as well as the relation between sex hormone levels and EDCs.

Methods: Drug-naïve transmen diagnosed with GD and who were referred from the psychiatry outpatient clinic to the outpatient clinic of the Department of Endocrinology, Marmara University Hospital, were included in the study. These individuals were assessed for eligibility; 38 drug-naïve transmen and 22 cis-women were recruited as the control group. After anthropometric evaluation laboratory tests for FSH, LH, total testosterone, and estradiol were carried out, spot urine samples were collected to evaluate the urine metabolic excretion of BPA, thiamethoxam, and fipronil.

Results: We found that androgens, total testosterone, androstenedione, and DHEAS levels were significantly higher in transmen than in cis-women. Thiamethoxam was considerably higher in cis-women than in transmen, whereas fipronil and BPA levels were similar in both groups. A negative correlation was found between thiamethoxam and testosterone and between thiamethoxam and BPA levels.

Conclusion: The available data suggest that the EDCs that we are most exposed to in our lives are not the only factor in GD development. Even transmen who have not taken hormone replacement have high testosterone levels; however, the mechanism has not as yet been elucidated. The challenge is to determine whether this is a factor leading to GD or a condition that develops in common with GD.

References
1.
Arcelus J, Bouman W, Noortgate W, Claes L, Witcomb G, Fernandez-Aranda F . Systematic review and meta-analysis of prevalence studies in transsexualism. Eur Psychiatry. 2015; 30(6):807-15. DOI: 10.1016/j.eurpsy.2015.04.005. View

2.
Swan S, Liu F, Hines M, Kruse R, Wang C, Redmon J . Prenatal phthalate exposure and reduced masculine play in boys. Int J Androl. 2009; 33(2):259-69. PMC: 2874619. DOI: 10.1111/j.1365-2605.2009.01019.x. View

3.
Bejerot S, Humble M, Gardner A . Endocrine disruptors, the increase of autism spectrum disorder and its comorbidity with gender identity disorder--a hypothetical association. Int J Androl. 2011; 34(5 Pt 2):e350. DOI: 10.1111/j.1365-2605.2011.01149.x. View

4.
Dessens A, Cohen-Kettenis P, Mellenbergh G, vd Poll N, Koppe J, Boer K . Prenatal exposure to anticonvulsants and psychosexual development. Arch Sex Behav. 1999; 28(1):31-44. DOI: 10.1023/a:1018789521375. View

5.
Konieczna A, Rachon D, Owczarek K, Kubica P, Kowalewska A, Kudlak B . Serum bisphenol A concentrations correlate with serum testosterone levels in women with polycystic ovary syndrome. Reprod Toxicol. 2018; 82:32-37. DOI: 10.1016/j.reprotox.2018.09.006. View